Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

Back to overview

10661studies shown

Showing 9,217-9,228 of 10,661

Drug study icon

CompletedNCT05021640

DCR-AUD in Healthy Volunteers

This summary needs review. Please check the official study record and contact the research team for details.

In United States

AddictionDrugFrom 21 Years to 65 Years

Countries: United States
Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Condition: Addiction

Drug study icon

CompletedNCT00181727

Depakote ER for Mania in Children Ages 6-12 With Bipolarity

This summary needs review. Please check the official study record and contact the research team for details.

In United States

BipolarityDrugFrom 6 Years to 12 Years

Countries: United States
Sponsor: Massachusetts General Hospital
Condition: Bipolarity

Drug study icon

CompletedNCT00278772

Divalproex Extended Release Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomania or Mild Mania

This summary needs review. Please check the official study record and contact the research team for details.

In United States

BipolarityDrugOver 18 Years

Countries: United States
Sponsor: Lindner Center of HOPE
Condition: Bipolarity

Behavioral study icon

CompletedNCT00983814

Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa

This summary needs review. Please check the official study record and contact the research team for details.

In United States

ADHDBehavioralFrom 18 Years to 55 Years

Countries: United States
Sponsor: Chelsea Therapeutics
Condition: ADHD

Drug study icon

CompletedNCT00607789

Duloxetine vs Placebo in Treatment of Binge Eating disorders With Depression

This summary needs review. Please check the official study record and contact the research team for details.

In United States

Depression, Eating disordersDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: University of Cincinnati
Condition: Depression, Eating disorders

Drug study icon

TerminatedNCT04722666

MIJ821 for depression

This study was terminated in the United States, in Canada, in Argentina, .... It is testing MIJ821 for depression.

In United States

Depression, SuicidalityDrugFrom 18 Years to 65 Years

Countries: United States, Canada, Argentina, ...
Sponsor: Novartis Pharmaceuticals
Condition: Depression, Suicidality

Behavioral study icon

CompletedNCT03751280

Efficacy of PEAR-004 in Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SchizophreniaBehavioralFrom 18 Years to 65 Years

Countries: United States
Sponsor: Novartis Pharmaceuticals
Condition: Schizophrenia

Drug study icon

CompletedNCT05454410

MIJ821 for treatment-resistant depression

This study is completed in the United States, in Japan, in Poland, .... It is testing MIJ821 for treatment-resistant depression.

In United States

DepressionDrugFrom 18 Years to 65 Years

Countries: United States, Japan, Poland, ...
Sponsor: Novartis Pharmaceuticals
Condition: Depression

Drug study icon

TerminatedNCT04933916

EMB-001 as a Potential Smoking Cessation Treatment

This summary needs review. Please check the official study record and contact the research team for details.

In United States

AddictionDrugFrom 21 Years to 65 Years

Countries: United States
Sponsor: Embera NeuroTherapeutics, Inc.
Condition: Addiction

Drug study icon

CompletedNCT01716975

EVP-6124 (Alpha-7 nAChR) for schizophrenia

This study is completed in the United States, in Australia, in the United Kingdom, .... It is testing EVP-6124 (Alpha-7 nAChR) for schizophrenia.

In United States

SchizophreniaDrugFrom 18 Years to 50 Years

Countries: United States, Australia, United Kingdom, ...
Sponsor: FORUM Pharmaceuticals Inc
Condition: Schizophrenia

Drug study icon

CompletedNCT01939353

Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) for ADHD

This study is completed in the United States. It is testing Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) for ADHD.

In United States

ADHDDrugFrom 18 Years to 55 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: ADHD

Other study type icon

CompletedNCT00342953

Health Effects of Cosmetic Breast Augmentation

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SuicidalityObservationalFrom 21 Years to 69 Years

Countries: United States
Sponsor: National Cancer Institute (NCI)
Condition: Suicidality

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.